IP Library Patent Application 17226799
Patent Application
App. No. 17/226,799

COMPOSITIONS COMPRISING DERMATAN SULFATE AND CHONDROITIN SULFATE AND USE THEREOF IN COSMETOLOGICAL COMPOSITIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/226,799
Abstract

The present invention is directed to a composition comprising from 0.1 to 10.0 wt % of a mixture of glycosaminoglycans comprising dermatan sulfate and chondroitin sulfate, wherein the amount of dermatan sulfate is at least 5% and not more than 95% by weight, and the amount of chondroitin sulfate is at least 5% and not more than 95% by weight, based on the total amount of glycosaminoglycans. Furthermore, the invention is also directed to the use of a glycosaminoglycans composition comprising dermatan sulfate and chondroitin sulfate, wherein the amount of dermatan sulfate is at least 5% and not more than 95% by weight, and the amount of chondroitin sulfate is at least 5% and not more than 95% by weight, based on the total amount of glycosaminoglycans, as an anti-age composition.

Claims (17)

1 . Composition comprising from 0.1 to 10.0 wt % of a mixture of glycosaminoglycans comprising dermatan sulfate and chondroitin sulfate, wherein the amount of dermatan sulfate is at least 5% and not more than 95% by weight, and the amount of chondroitin sulfate is at least 5% and not more than 95% by weight, based on the total amount of glycosaminoglycans, and wherein the composition comprises less than 5% hyaluronic acid, wherein the weight ratio of dermatan sulfate to chondroitin sulfate is comprised between 50/50 and 90/10.

2 . Composition according to claim 1 wherein the amount of dermatan sulfate is at least 10% and not more than 90%, and the amount of chondroitin sulfate is at least 10% and not more than 90 wt %, based on the total amount of glycosaminoglycans.

3 . Cosmetological composition comprising the composition of claim 1 .

4 . Cosmetological composition according to claim 3 wherein the glycosaminoglycans mixture is present in an amount from 0.5 to 5% by weight, based on the total composition.

5 . Cosmetological composition according to claim 4 wherein the glycosaminoglycans mixture comprises at least another glycosaminoglycan.

6 . Cosmetological composition according to claim 4 wherein the glycosaminoglycans mixture consists of a mixture of dermatan sulfate and chondroitin sulfate.

7 . Cosmetological composition according to claim 3 , wherein the composition is in the form of an aqueous solution, liquid or in a viscous form, and further comprises water, and optionally other additives selected from humectants, anti-oxidants, preservatives, stabilizers, and other compounds which are commonly used in cosmetic gels.

8 . Cosmetological composition according to claim 3 , wherein the composition is in the form of a cream and further comprises at least one oil and or silicon or fat selected from natural and synthetic oil/fat or mixtures thereof, one or more emulsifiers selected from ionic and non-ionic emulsifiers, and optionally water and other additives selected from humectants, anti-oxidants, preservatives, stabilizers, and other compounds which are commonly used in cosmetic creams.

9 . A method of administering a glycosaminoglycan composition comprising dermatan sulfate and chondroitin sulfate, wherein the amount of dermatan sulfate is at least 5% and not more than 95% by weight, and the amount of chondroitin sulfate is at least 5% and not more than 95% by weight, based on the total amount of glycosaminoglycans, and wherein the composition comprises less than 5% hyaluronic acid, as an anti-age composition or an anti-wrinkle composition .

10 . A glycosaminoglycans mixture comprising dermatan sulfate and chondroitin sulfate, wherein the amount of dermatan sulfate is at least 20% and not more than 90% by weight, and the amount of chondroitin sulfate is at least 10% and not more than 80% by weight, based on the total amount of glycosaminoglycans, wherein dermatan sulfate and chondroitin sulfate together are present in an amount that is at least 40 wt % of the total amount of GAGs, the amount of heparin is lower than 5 wt % and wherein the composition is substantially free of hyaluronic acid, wherein the weight ratio of dermatan sulfate to chondroitin sulfate is comprised between 50/50 and 90/10.

11 . Composition according to claim 10 wherein the weight ratio dermatan sulfate to chondroitin sulfate is comprised between 75/25 and 90/10.

12 . Composition according to claim 11 , further comprising heparan sulfate.

13 . Composition according to claim 10 , wherein dermatan sulfate and chondroitin sulfate together are present in an amount that is at least 60 wt % of the total amount of GAGs.

14 . Orally administrable composition comprising the glycosaminoglycans composition according to claim 10 .

15 . Orally administrable composition comprising the glycosaminoglycans composition according to claim 11 .

16 . Orally administrable composition comprising the glycosaminoglycans composition according to claim 12 .

17 . Orally administrable composition comprising the glycosaminoglycans composition according to claim 13 .

Assignments (1)
MERGER Recorded Mar 12, 2025
From: LABORATORI DERIVATI ORGANICI S.P.A.
To: OPOCRIN S.P.A.
Reel/Frame 070491/0169 →